Johan Baeck, MD | Source | Executive Vice President, Chief Medical Officer at Promontory Therapeutics
Johan Baeck, MD
Dr. Baeck is the Executive Vice President and Chief Medical Officer at Promontory Therapeutics. He is an experienced industry clinician with deep expertise in oncology clinical development. Dr Baeck’s focus over the last years has been on the development of novel therapeutic approaches in oncology, specializing in small molecules, immunotherapy, and biologic agents for the treatment of solid tumors and hematologic malignancies.
-
Patients with late-stage mCRPC currently have very limited treatment options that are both effective and durable. Although many trials are being conducted in prostate cancer, there are few agents with new mechanisms of action similar to PT-112. Pre-clinical research suggests that that PT-112 induces immunogenic cell death and osteotropism, and our prior dose escalation trials showed preliminary evidence of the safety, efficacy, and clinical benefit of PT-112 in mCRPC patients. We are looking forward to completing enrollment of this study in 2024 and sharing clinical and biomarker data upon completion of the study.
-
Promontory Therapeutics Presents Phase 2 Trial in Progress for PT-112 in Prostate Cancer at 2023 ASCO Genitourinary Cancers Symposium
Promontory Therapeutics Inc., a clinical stage pharmaceutical company advancing small molecule immunotherapies in oncology, today presented its Phase 2 clinical trial in progress of lead therapeutic candidate, PT-112, in patients with late-stage metastatic castration-resistant prostate cancer (mCRPC). The poster presentation took place at the 2023 American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium, in San Francisco.
Article
-
Promontory Therapeutics
Executive Vice President, Chief Medical Officer